Core Insights - Artiva Biotherapeutics is advancing its AlloNK therapy in clinical trials for autoimmune diseases, with over a dozen patients treated and multiple sites enrolling [1][2][6] - Initial safety and translational data for AlloNK are expected to be presented by the end of 2025, with initial clinical response data anticipated in the first half of 2026 [1][6] Company Overview - Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing cell therapies for autoimmune diseases and cancers, with its lead program being AlloNK (AB-101) [7] - AlloNK is designed to enhance the efficacy of monoclonal antibodies in treating B-cell driven autoimmune diseases [7] Clinical Trials Progress - The company has initiated a global Phase 2a basket trial for refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies, and systemic sclerosis, with the first patient treated [1][6] - Over a dozen patients have been treated with AlloNK in combination with monoclonal antibodies across various autoimmune diseases [2][6] Financial Highlights - As of June 30, 2025, Artiva reported cash, cash equivalents, and investments totaling $142.4 million, which is projected to fund operations into Q2 2027 [5][11] - Research and development expenses for Q2 2025 were $17.9 million, an increase from $12.3 million in Q2 2024 [11][13] Upcoming Milestones - By the end of 2025, the company plans to disclose initial safety and translational data for AlloNK, as well as its lead indication for further development [6] - Initial clinical response data in the lead indication is expected to be shared in the first half of 2026 [6]
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights